NCT03871816 – A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer Posted on September 25, 2026 by Molly Willeford -
NCT03748641 – A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) Posted on September 25, 2026 by Molly Willeford -
NCT03201965 – A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis Posted on April 17, 2026 by Molly Willeford -
NCT03462719 – A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW) Posted on November 26, 2025 by Molly Willeford -
NCT02959944 – Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE) Posted on October 27, 2025 by Molly Willeford -
NCT03871829 – A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab to Evaluate Daratumumab Retreatment Posted on July 24, 2025 by Molly Willeford -
NCT03390504 – A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations Posted on April 29, 2025 by Molly Willeford -
NCT02874742 – Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Posted on October 28, 2024 by Molly Willeford -
NCT02703272 – A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma Posted on October 28, 2024 by Molly Willeford -
NCT02365597 – An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer Posted on September 5, 2024 by Molly Willeford -
The YODA Project